Revenue: As of FY2026 Q2, the actual value is USD 7.659 M, missing the estimate of USD 12.98 M.

EPS: As of FY2026 Q2, the actual value is USD -0.8, missing the estimate of USD -0.7871.

EBIT: As of FY2026 Q2, the actual value is USD -112.43 M.

Cash Position

Intellia Therapeutics, Inc. reported cash, cash equivalents, and marketable securities of $628.4 million as of June 30, 2026, an increase from $605.1 million as of December 31, 2025. In April 2026, the company generated approximately $195 million in net proceeds from a public offering of its common stock.

Collaboration Revenue

Collaboration revenue for the second quarter of 2026 was $7.7 million, a decrease compared to $14.2 million for the second quarter of 2025. This decline was primarily due to a reduction in revenue from Regeneron. For the six months ended June 30, 2026, collaboration revenue was $22.7 million, down from $30.872 million for the same period in 2025.

Operating Expenses

Research and Development (R&D) Expenses

R&D expenses for the second quarter of 2026 were $82.6 million, down from $97.0 million in the second quarter of 2025. The decrease was mainly attributed to lower external costs related to lead development programs and reduced stock-based compensation, partially offset by increased employee-related expenses. Stock-based compensation expense included in R&D was $9.4 million for the second quarter of 2026. For the six months ended June 30, 2026, R&D expenses were $163.332 million, compared to $205.462 million for the same period in 2025.

General and Administrative (G&A) Expenses

G&A expenses increased to $37.8 million for the second quarter of 2026, up from $27.2 million for the second quarter of 2025. This increase was primarily driven by costs associated with building out the company’s commercial infrastructure, higher legal expenses, and stock-based compensation. Stock-based compensation expense included in G&A was $8.6 million for the second quarter of 2026. For the six months ended June 30, 2026, G&A expenses were $72.667 million, compared to $56.213 million for the same period in 2025.

Total Operating Expenses

Total operating expenses for the second quarter of 2026 were $120.419 million, a slight decrease from $124.241 million in the second quarter of 2025. For the six months ended June 30, 2026, total operating expenses were $235.999 million, compared to $261.675 million for the same period in 2025.

Operating Loss

Intellia Therapeutics, Inc. reported an operating loss of - $112.760 million for the second quarter of 2026, compared to an operating loss of - $109.996 million for the second quarter of 2025. For the six months ended June 30, 2026, the operating loss was - $213.292 million, an improvement from - $230.803 million for the same period in 2025.

Other Income, Net

Total other income, net, was $6.126 million for the second quarter of 2026, compared to $8.741 million for the second quarter of 2025. This included interest income of $5.797 million (Q2 2026) versus $7.402 million (Q2 2025) and a change in fair value of investments, net, of $0.329 million (Q2 2026) versus $1.339 million (Q2 2025). For the six months ended June 30, 2026, total other income, net, was $10.427 million, compared to $15.219 million for the same period in 2025.

Net Loss

Net loss for the second quarter of 2026 was - $106.6 million, compared to - $101.3 million for the second quarter of 2025. For the six months ended June 30, 2026, the net loss was - $202.865 million, an improvement from - $215.584 million for the same period in 2025.

Balance Sheet Data (in thousands)

• Total Assets: $857,164 as of June 30, 2026, compared to $842,127 as of December 31, 2025.
• Total Liabilities: $129,458 as of June 30, 2026, compared to $170,733 as of December 31, 2025.
• Total Stockholders’ Equity: $727,706 as of June 30, 2026, compared to $671,394 as of December 31, 2025.

Operational Metrics

Intellia Therapeutics, Inc. announced positive Phase 3 HAELO clinical data for lonvo-z in HAE, which met its primary endpoint by reducing attacks by 87% versus placebo over a six-month efficacy period. All key secondary endpoints were also met with statistical significance. For nex-z, enrollment in Phase 3 clinical trials was successfully reinitiated, with MAGNITUDE-2 enrollment in ATTRv-PN expected to be completed in the second half of 2026.

Outlook and Guidance

Intellia Therapeutics, Inc. anticipates FDA acceptance of a Biologics License Application (BLA) for lonvo-z in the second half of 2026, with a planned U.S. commercial launch in the first half of 2027. The company also expects to complete patient enrollment in the MAGNITUDE-2 Phase 3 clinical trial for nex-z in hereditary ATTR amyloidosis with polyneuropathy during the second half of 2026. Existing cash resources are projected to fund operations at least into 2028, excluding potential commercial revenues from lonvo-z.